DPP4

Dipeptidyl peptidase 4 · P27487 · DPP4 on Sugi Atlas →

300,521 patent compounds predicted against DPP4, 141,069 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Saxagliptin Anhydrous (SCHEMBL17168)	1.00	20/20
Sitagliptin (SCHEMBL17783)	1.00	20/20
Vildagliptin (SCHEMBL16579)	1.00	17/20
SCHEMBL82202	0.51	11/20
SCHEMBL69147	0.46	8/20
SCHEMBL85637	0.50	7/20
Trovafloxacin (SCHEMBL34465)	0.55	6/20
Trovafloxacin (SCHEMBL34466)	0.55	6/20
Trovafloxacin (SCHEMBL40874)	0.51	6/20
Trovafloxacin (SCHEMBL40875)	0.51	6/20
SCHEMBL99343	0.42	6/20
Alatrofloxacin (SCHEMBL41134)	0.42	6/20
SCHEMBL41135	0.42	6/20
SCHEMBL85622	0.33	6/20
SCHEMBL99033	0.42	5/20
SCHEMBL99711	0.42	5/20
Hydrochloric Acid (SCHEMBL75462)	0.41	5/20
SCHEMBL27005	0.38	5/20
Licoagrochacone A (SCHEMBL114042)	1.00	4/20
Delphinidin (SCHEMBL22369)	0.71	4/20

Clinical trials — most relevant to DPP4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of Saxagliptin on Glucose Fluctuation and Immune Regulation in Patients With Type 1 Diabetes	PHASE4	UNKNOWN
Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors	PHASE4	UNKNOWN
SNP Study of DPP-4 and GLP-1R in Chinese People (Including Diabetes Patients)	PHASE4	COMPLETED
Incretins in Impaired Fasting Glucose	PHASE4	COMPLETED
Correlation Between Plasma- and Endothelial DPP-4 Activity	PHASE4	COMPLETED
The Effect of Sitagliptin, Pioglitazone and Dapagliflozine on Myocardial Infarction in Diabetic Rats	PHASE4	COMPLETED
Effects of Sitagliptin in Individuals With Genetically Decreased DPP4	PHASE4	ACTIVE_NOT_RECRUITING
Effect of Gemigliptin Versus Glimepiride on Cardiac Diastolic Function in Patients With Type 2 Diabetes	PHASE4	UNKNOWN
Effects of DPP4 Inhibition on COVID-19	PHASE4	WITHDRAWN
Sitagliptin for the Treatment of Type 2 Diabetes	PHASE4	UNKNOWN
The Effects of Neprilysin on Glucagon-like Peptide-1	PHASE4	COMPLETED
Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas	PHASE4	COMPLETED
Effect of DPP4 Inhibition on Vasoconstriction	PHASE4	COMPLETED
Effect of Dipeptidyl Peptidase- 4 Inhibitors on Non-Alcoholic Steatohepatitis and Type 1 Diabetes	PHASE3	COMPLETED
Long Term Effects of DPP-IV Inhibitor Treatment in Patients With Type 2 Diabetes	PHASE3	COMPLETED
Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)	PHASE3	COMPLETED
The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients	PHASE3	UNKNOWN
Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency	PHASE2	COMPLETED
Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.	PHASE2	COMPLETED
Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus	PHASE2	COMPLETED
Effect of Sitagliptin on Incretin Effect in Patients With Type 2 Diabetes Mellitus	PHASE1	COMPLETED
Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals	PHASE1	COMPLETED
The Incretin Effect in Patients With Kidney Impairment	nan	COMPLETED
Emulation of the SOUL Diabetes Trial in Healthcare Claims	nan	COMPLETED
DPP4 Activity, Microvascular Reactivity and Inflammation	nan	COMPLETED
Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure	nan	COMPLETED
Effect of Dipeptidyl Peptidase IV After Diets in näive Type 2 Diabetic Patients	nan	COMPLETED
Emulating the PIONEER6 Diabetes Trial Using Healthcare Claims	nan	COMPLETED
Incretin-based Drugs and Acute Pancreatitis	nan	COMPLETED
Perioperative Sitagliptin Medication for Reduction of the Inflammatory Response Associated With Cardiopulmonary Bypass	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a DPP4 binder may also engage these)

Protein	Name	Similarity
P28843	—	1.000	P28843 →
Q9Z218	—	1.000	Q9Z218 →
P22411	—	1.000	P22411 →
P0DRB8	—	1.000	P0DRB8 →
B2D0J4	—	1.000	B2D0J4 →
B1A4F7	—	0.999	B1A4F7 →
Q9N2I7	—	0.999	Q9N2I7 →
P14740	—	0.998	P14740 →
P81425	—	0.997	P81425 →
FAP	Prolyl endopeptidase FAP	0.996	landscape →
A5D7B7	—	0.996	A5D7B7 →
O14073	—	0.996	O14073 →
P42658	—	0.995	P42658 →
Q5IS50	—	0.995	Q5IS50 →
B6V868	—	0.993	B6V868 →
A1CHP1	—	0.992	A1CHP1 →
Q6NXK7	—	0.991	Q6NXK7 →
Q18253	—	0.991	Q18253 →
P18962	—	0.991	P18962 →
P97321	—	0.990	P97321 →
Q9P778	—	0.989	Q9P778 →
Q2UH35	—	0.988	Q2UH35 →
P97449	—	0.988	P97449 →
P85841	—	0.988	P85841 →
Q8N608	—	0.988	Q8N608 →
Q10916	—	0.987	Q10916 →
W4VSJ0	—	0.987	W4VSJ0 →
P42659	—	0.987	P42659 →
B0Y6C5	—	0.986	B0Y6C5 →
Q5GRG2	—	0.986	Q5GRG2 →